DEVELOPING DRUG THERAPIES FOR CNS DISEASES

There has never been a greater need for the development of new and effective medicines for the treatment of diseases. However, the costs for creating new drugs have skyrocketed and therapies for many diseases are not being developed because the patient population is too small to be profitable.

A new organizational model is necessary to translate discoveries with therapeutic potential into clinically useful compounds.  

The Falk Center for Molecular Therapeutics is such a model.

We are a molecular biology-based drug discovery Center of Excellence within the Biomedical Engineering Department of McCormick School of Engineering and Applied Science at Northwestern University, tethered to a biotechnology company, Naurex, Inc. (“Naurex”).

 

 

The lead compound, GLYX-13, has successfully passed through a Phase I human clinical trial and is currently entering a Phase II trial for treatment-resistant depression (Press Releases). Interestingly, based on animal study data, GLYX-13 appears to have therapeutic potential for neuropathic pain, schizophrenia and autism.  Read more